BGB-A333 is an investigational humanized IgG1 monoclonal antibody against PD-L1 that has antitumor activity in xenograft models. Tislelizumab, a clinical-stage anti-PD-1 antibody engineered to minimize binding to Fc纬R on macrophages in order to abrogate antibody-dependent phagocytosis, has ...
百济神州主营产品名称 HK6160主营产品名称BGB-10188、BGB-11417、BGB-15025、BGB-A333、BGB-A425、BGB-A445、lifirafenibBGB-283、ociperlimabBGB-A1217、帕米帕利BGB-290、替雷利珠单抗注射液百泽安BGB-A317、泽布替尼胶囊百悦泽/BRUKINSABGB-3111
(PD-L1) checkpoint inhibitors due to secondary or acquired resistance; therefore, there is a need to investigate novel PD-1/PD-L1 inhibitors.Methods This open-label, non-randomised study investigated the safety and anti-tumour activity of BGB-A333, a PD-L1 inhibitor, alone and in combination...
535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma - ScienceDirectdoi:10.1016/j.annonc.2020.08.649J. Martin LiberalP.C. FongV. MorenoS. FrentzasJ. DesaiT. Meniawy...